Real-World Outcomes With Intravitreal Syfovre and Izervay in High-Volume Private Retina Clinic: A Two-Year Study

Document Type

Conference Proceeding

Publication Date

6-2026

Publication Title

Investigative Ophthalmology and Visual Science

Abstract

Purpose : Following FDA approval of Syfovre and Izervay in 2023, practice patterns for the treatment of Geographic Atrophy have transformed while there continues to be insufficient research about long-term outcomes for these medications in daily clinical practice. Restricted by limited long-term data, we evaluated the “real-world” outcomes of intravitreal Syfovre (IVS) and Izervay (IVI) for the treatment of Geographic Atrophy.

Methods : This ongoing, retrospective study observed patients receiving IVS or IVI from May 2023 to May 2025 in a single, private retina clinic with multiple providers. Preliminary data analysis of subjective vision complaints, best corrected visual acuity (BCVA), and treatment emergent adverse events (AEs) was completed for the first year of the study. Statistical significance was assessed by paired t-test.

Results : To-date, 5349 injections (IVS=4420, IVI=929) were administered to 1128 eyes in 582 patients. Over one year, LogMAR BCVA baseline to last follow up was 0.78±0.6 to 0.65±0.5 in IVS; and 0.87±0.7 to 0.66±0.6 in IVI, respectively. 45.6% of treated eyes improved BCVA, with an average gain of 12 letters (p=0.03). In the same year, 32.9% of unique eyes experienced subjective vision changes (SVC) upon first starting anti-complement. Complaints included darkened vision (42.4%), color changes/photopsia (4.1%), floaters (9.6%), and ocular irritation (2.7%). Of those with SVC, 86.3% had received IVS and 13.7% had received IVI. In response, anti-complement was paused in 8.9% of eyes, substituted with alternative AC in 19.9%, and continued in 71.2%. In eyes with SVC, 84 eyes were clinically stable, while 62 eyes showed new post-AC exudation. Of the 62 eyes with SVC and new exudation, 42.5% were co-treated with anti-VEGF therapy during AC treatments without complications. Severe AEs included: 15.3% post AC therapy exudation, 0.17% severe, occlusive vasculitis, and no cases of endophthalmitis. One eye developed retinal vasculitis confirmed by angiography and was treated with prednisone, difluprednate, and pressure-lowering drops; at month 2, logMAR BCVA plateaued at 1.3 from 0.47. One eye underwent RD repair following IVS and IV faricimab. VA returned to baseline in 75% of eyes with TEAEs.

Conclusions : Our data reflects preliminary outcomes of IVS/IVI in routine clinical practice. Final analysis is pending.

Volume

67

Issue

7

First Page

134

Comments

Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting, May 3-7, 2026, Denver, CO

Last Page

134

Link to Full Text

Share

COinS